Acrivon advances ACR-2316 into randomized dose expansion in Phase 1/2 trial
ACRV•Phase 1/2 trial moves into dose expansion
Acrivon Therapeutics advanced ACR-2316 into randomized dose expansion in its ongoing Phase 1/2 trial, based on dose-escalation safety and activity observations.
Results have already been presented as interim findings from dose escalation; additional updates are expected as the expansion progresses.
Early activity supports continued development
Early outcomes showed durable single-agent anti-tumor activity, including responses in heavily pretreated patients, with tolerability supporting continued development.
The study will randomize 120 mg versus 160 mg once-daily dosing on a weekly 3-days-on, 4-days-off schedule to support final dose selection.
Expansion will focus on biomarker-selected solid tumors, led by lung cancer cohorts, aiming to sharpen the benefit-risk profile for later-stage trials.
